Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Read More →
Enzalutamide 40 mg
Enzalutamide is an oral prescription anticancer medicine used to treat certain forms and stages of prostate cancer. It belongs to a group of medicines known as androgen-receptor inhibitors or androgen-receptor signaling inhibitors. Prostate cancer can be influenced by male sex hormones called androgens, particularly testosterone. These hormones can activate androgen receptors in prostate cancer cells and stimulate signaling pathways involved in cancer-cell growth and survival.
What Is Enzalutamide?
Enzalutamide works by interfering with androgen-receptor signaling. By reducing the ability of prostate cancer cells to respond to androgen stimulation, it can help control the disease in patients for whom the medicine is appropriate. Enzalutamide is different from conventional cytotoxic chemotherapy. Rather than primarily attacking rapidly dividing cells through traditional cytotoxic mechanisms, it specifically targets androgen-receptor signaling. Treatment should be initiated and monitored by a healthcare professional experienced in the medical management of prostate cancer.
Everest Pharmaceuticals Ltd. About the Manufacturer
Generic Name: Enzalutamide
Brand/Product Name: Enzamide
Strength: 40 mg
Company: Everest Pharmaceuticals Ltd.
Medicine Type: Prescription anticancer medicine
Therapeutic Class: Androgen-receptor inhibitor / androgen-receptor signaling inhibitor
Dosage Form: Oral medicine
Head Office: Everest Pharmaceuticals Ltd. is located at Rahman’s Regnum Centre (10th & 11th floor), 191/1 Tejgaon Commercial Area, Dhaka-1208, Bangladesh.
Manufacturing Plant: Everest Pharmaceuticals Limited B-33, 45 & 46, BSCIC, Kanchpur, Narayanganj–1430, Bangladesh. Ribokis 200 mg (Ribociclib) is manufactured by Everest Pharmaceuticals Ltd., a pharmaceutical company based in Bangladesh.
What Is Enzalutamide 40 mg?
Enzamide 40 mg is the product identified in the supplied website information as containing enzalutamide, with Everest listed as the company.
The 40 mg strength refers to the amount of enzalutamide contained in an individual dosage unit. The strength of an individual tablet should not automatically be interpreted as the patient’s total daily dose.
The appropriate daily regimen depends on the patient’s diagnosis, treatment setting, other medicines, tolerability, and applicable prescribing information.
Product-specific regulatory authorization, manufacturing information, packaging, and marketing authorization details should be checked against the actual product documentation before publication, dispensing, or purchase.
What Is Enzalutamide Used For?
Enzalutamide is used in specific prostate-cancer treatment settings. It is not intended for every type or stage of prostate cancer.
Current European product information describes enzalutamide use in several settings, including:
High-Risk Biochemical Recurrent Non-Metastatic Hormone-Sensitive Prostate Cancer
Enzalutamide may be used in adult men with high-risk biochemical recurrent, non-metastatic hormone-sensitive prostate cancer who are unsuitable for salvage radiotherapy, according to the applicable indication.
Metastatic Hormone-Sensitive Prostate Cancer
Enzalutamide may be used for metastatic hormone-sensitive prostate cancer in combination with androgen-deprivation therapy.
High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
Enzalutamide has an established treatment role in certain men with high-risk non-metastatic castration-resistant prostate cancer.
Metastatic Castration-Resistant Prostate Cancer
Enzalutamide may be used in specified patients with metastatic castration-resistant prostate cancer, including certain patients whose disease has progressed following androgen-deprivation therapy and patients who have progressed on or after docetaxel.
The exact indication, eligibility criteria, treatment combination, and treatment sequence can vary according to regulatory jurisdiction and the individual patient’s clinical circumstances.
Which Disease Does Enzalutamide Treat?
The principal disease treated with enzalutamide is prostate cancer.
However, prostate cancer is not a single clinical condition. Doctors classify it according to factors such as:
Whether it is localized or metastatic
Whether it remains hormone-sensitive
Whether it has become castration-resistant
Previous treatments
PSA behavior
Imaging findings
Symptoms
Overall health
Enzalutamide is therefore prescribed only when the patient’s clinical situation matches an appropriate indication.
How Does Enzalutamide Work?
Enzalutamide targets the androgen receptor, which plays an important role in prostate-cancer biology.
In simplified terms:
Androgen → androgen receptor → signaling → prostate-cancer growth
Enzalutamide interferes with this pathway.
It inhibits androgen-receptor signaling by interfering with androgen binding and receptor activity. This reduces androgen-driven gene signaling in prostate-cancer cells.
Because the medicine acts on hormone signaling rather than functioning as conventional cytotoxic chemotherapy, it is generally classified as targeted hormonal therapy.
Enzalutamide 40 mg Dosage
The dose of enzalutamide must be determined by the treating healthcare professional.
Current European product information for the reference medicine Xtandi recommends an adult dose of 160 mg once daily. This corresponds to four 40 mg tablets or two 80 mg tablets.
This information is provided for general educational purposes and must not be treated as an individualized prescription.
A physician may modify or interrupt treatment when clinically appropriate, including when adverse reactions occur.
Patients should never increase, reduce, or otherwise change their prescribed dose without medical advice.
How and When Should Enzalutamide Be Taken?
Enzalutamide is taken orally.
Reference product information describes once-daily administration, generally at approximately the same time each day.
Patients should:
Take enzalutamide exactly as prescribed.
Follow the instructions provided with their specific product.
Take the medicine at approximately the same time each day.
Avoid changing the dose independently.
Avoid stopping treatment without speaking with their doctor.
Tell their healthcare professional about other medicines and supplements.
Maintaining a consistent daily routine may help patients remember their treatment.
Should Enzalutamide Be Taken With Food?
Reference product information permits enzalutamide to be administered with or without food.
Patients should nevertheless follow the instructions supplied with their particular product and prescription.
Food instructions should not be changed deliberately without checking the applicable product information.
What If a Dose Is Missed?
Patients should follow the missed-dose instructions provided with their specific product or contact their healthcare professional or pharmacist.
Do not automatically take an extra dose to compensate for a missed dose.
If there is uncertainty about what to do after a missed dose, professional advice should be obtained.
Can Enzalutamide Be Stopped?
Patients should not stop enzalutamide independently, even if they feel better.
Prostate cancer treatment is generally based on an ongoing treatment strategy, and stopping or changing therapy can affect that strategy.
If a patient experiences side effects or has concerns about treatment, the appropriate response is to discuss them with the treating physician.
Important Precautions and Warnings
Enzalutamide can cause clinically important adverse effects and requires appropriate medical supervision.
Important safety considerations include:
Seizures
Ischemic heart disease
Falls
Fractures
Hypertension
Posterior reversible encephalopathy syndrome
Hypersensitivity reactions
Fatigue
Dizziness
Headache
Hot flushes
Other neurological or cognitive effects
Seizure Risk
Seizures are an important identified risk associated with enzalutamide.
Patients should tell their healthcare professional if they have a history of:
Seizures
Brain injury
Stroke
Neurological disease
Other conditions associated with increased seizure risk
A seizure during treatment requires prompt medical assessment.
Cardiovascular Considerations
Ischemic heart disease is an important safety consideration.
Patients should tell their physician about existing cardiovascular disease and relevant risk factors.
Symptoms such as severe chest pain, pressure, or significant breathing difficulty require urgent medical evaluation.
Falls and Fractures
Falls and fractures may occur during treatment.
Risk can be affected by age, bone health, dizziness, weakness, balance problems, other medicines, and other medical conditions.
Patients who experience repeated falls or suspected fractures should inform their healthcare professional.
Common Side Effects of Enzalutamide
Reported adverse effects can include:
Fatigue
Hot flushes
Hypertension
Headache
Dizziness
Falls
Fractures
Other treatment-related effects
The frequency and severity of adverse reactions can vary according to the treatment setting and individual patient.
Patients should report persistent, severe, or worsening symptoms to their healthcare professional.
Serious Side Effects
Some symptoms require urgent medical attention.
Seek immediate medical help for symptoms such as:
Seizure
Severe chest pain
Severe breathing difficulty
Facial, tongue, or throat swelling
Severe allergic symptoms
Sudden confusion
Significant vision changes
Severe neurological symptoms
Loss of consciousness
A serious symptom should not be ignored or assumed to be a routine side effect.
Who Should Avoid or Not Take Enzalutamide?
Enzalutamide should not be used simply because someone has prostate cancer.
It is appropriate only when a qualified healthcare professional determines that the patient’s diagnosis and clinical circumstances match an approved treatment indication.
Patients should discuss their medical history before treatment, particularly if they have:
A history of seizures
Neurological conditions
Cardiovascular disease
Hypertension
Problems with falls
Bone-health concerns
Medicine allergies
Other significant medical conditions
Enzalutamide is not intended for women as a prostate cancer treatment. Current European information states that Xtandi must not be given to women who are or may become pregnant.
Enzalutamide Drug Interactions
Enzalutamide can interact with other medicines.
It can affect drug-metabolizing enzymes and transport pathways, potentially changing the exposure or effectiveness of other medicines.
Before starting treatment, patients should provide a complete list of:
Prescription medicines
Over-the-counter medicines
Vitamins
Herbal products
Nutritional supplements
Anticancer medicines
Medicines for epilepsy
Cardiovascular medicines
Blood-pressure medicines
Patients should not begin a new medicine, supplement, or herbal product without checking whether it is appropriate to use alongside enzalutamide.
Enzalutamide and Food Interactions
Reference product information permits enzalutamide to be taken with or without food.
However, food instructions for the specific marketed product should always be checked against its official labeling.
The more significant interaction concern with enzalutamide generally relates to other medicines rather than ordinary food.
Patients should inform their healthcare professional about supplements and herbal products because these may also affect medicine treatment.
Enzalutamide and Other Prostate-Cancer Treatments
Enzalutamide may be used as part of a broader prostate-cancer treatment plan.
For example, current European information describes its use with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer.
For certain men with castration-resistant prostate cancer who have not undergone surgical castration, medical castration using an LHRH analogue should continue according to applicable product information.
The complete treatment plan should always be determined by the treating oncology team.
Available Strengths and Forms
For the product covered by this website, the supplied information identifies:
| Product | Active Ingredient | Strength |
|---|---|---|
| Enzamide | Enzalutamide | 40 mg |
Current European product information for the reference medicine Xtandi includes 40 mg and 80 mg film-coated tablets.
The availability of particular strengths and dosage forms can vary between countries and products.
Patients should use only the strength and dosage form prescribed for them.
Active Ingredient
The active ingredient in Enzamide 40 mg is:
Enzalutamide — 40 mg per dosage unit
Enzalutamide is an androgen-receptor signaling inhibitor.
The active ingredient is responsible for the medicine’s pharmacological activity against androgen-receptor signaling in prostate cancer.
Is Enzamide the Same as Xtandi?
Enzamide and Xtandi should not automatically be described as identical products merely because they may contain the same active ingredient.
The supplied information identifies Enzamide 40 mg as containing enzalutamide.
Xtandi is an established reference medicine containing enzalutamide.
Whether two particular products are therapeutically interchangeable depends on applicable regulatory authorization, pharmaceutical documentation, formulation, strength, and prescribing requirements.
Patients should follow the medicine prescribed or dispensed to them.
Everest Pharmaceuticals Ltd. Product Verification Process
To verify the authenticity of an Everest Pharmaceuticals product, follow the verification process below:
Scan the QR Code: Scan the QR code printed on the product box. The QR code will direct you to the official product verification page.
Open the Box: After accessing the verification page, open the product box and locate the verification code printed on the bottle.
Submit the Verification Code: Enter the verification code from the bottle on the verification page and submit it to check the product’s authenticity.
Verification Success: If the verification is successful, the product is confirmed as legitimate.
Verification Error: If the system displays a verification error, the product may be counterfeit or unauthorized. Do not use the product until its authenticity has been confirmed through an appropriate official channel.
Counterfeit Products: If a product is confirmed to be fake, do not use or distribute it. Report the suspected counterfeit product and supplier to the appropriate regulatory authorities, such as the Directorate General of Drug Administration (DGDA) in World, and take appropriate legal action against the supplier through the relevant authorities.
Important: Always purchase medicines from licensed pharmacies or authorized suppliers and verify suspicious products before use.
Storage Instructions
Storage requirements should be taken directly from the official product labeling supplied with the specific medicine.
Patients should:
Keep the medicine in its original packaging where appropriate.
Follow the storage temperature and handling instructions on the package.
Keep medicines away from children.
Check the expiry date before use.
Avoid using medicine with damaged packaging unless a pharmacist confirms it is appropriate.
Do not assume that storage conditions for one enzalutamide product automatically apply to every marketed product.
Monitoring During Treatment
Regular medical follow-up is important during enzalutamide treatment.
Depending on the patient’s condition, the healthcare team may monitor:
Prostate-cancer status
PSA results
Symptoms
Treatment response
Blood pressure
Cardiovascular health
Neurological symptoms
Falls and fractures
Adverse reactions
Other medicines
Relevant laboratory results
Imaging findings where clinically appropriate
The exact monitoring schedule is individualized.
Pregnancy and Reproductive Considerations
Enzalutamide is intended for prostate cancer treatment in men.
It is not indicated for women, and current European product information states that Xtandi must not be given to women who are or may become pregnant.
Because androgen-signaling medicines may present reproductive risks, patients should follow the contraception and reproductive precautions specified in the applicable official product information.
Patients should discuss reproductive considerations with their healthcare professional if relevant.
Does Enzalutamide Cure Prostate Cancer?
Enzalutamide should not be described as a guaranteed cure for prostate cancer.
Its purpose is to interfere with androgen-receptor signaling and treat specific prostate-cancer conditions.
The goal of treatment may include controlling disease, delaying progression, or maintaining disease control, depending on the patient’s clinical situation.
Treatment response varies between individuals and must be assessed by the treating healthcare team.
Who Should Prescribe Enzalutamide?
Enzalutamide should be prescribed and supervised by an appropriately qualified healthcare professional experienced in prostate cancer treatment.
The doctor considers:
Cancer stage
Hormone sensitivity
Metastatic status
Previous treatment
PSA and other clinical information
Other health conditions
Current medicines
Potential drug interactions
Expected benefits and risks
Patients should not use enzalutamide based solely on online information.
Key Patient Information
Before starting Enzamide 40 mg, patients should understand:
Enzamide contains enzalutamide.
It is a prescription anticancer medicine.
It is used for specific prostate-cancer treatment settings.
It is an androgen-receptor inhibitor.
It is generally taken orally once daily according to the prescription.
Reference product information permits administration with or without food.
The reference adult dose is 160 mg once daily, but this does not constitute an individualized prescription.
Enzalutamide can interact with other medicines.
Seizures and cardiovascular problems are important safety considerations.
Patients should not change or stop treatment without medical advice.
Regular follow-up is important.
Product-specific information should be verified against official packaging and documentation.
Medical Disclaimer
This information is provided for educational purposes and does not replace professional medical advice, diagnosis, or treatment.
Enzalutamide is a prescription anticancer medicine. Patients should not start treatment, change the dose, stop treatment, or modify the treatment schedule based solely on information found on this website.
Always follow the instructions of the prescribing healthcare professional and the official product information applicable to the medicine supplied to you.
| Information | Details |
|---|---|
| Medicine | Enzamide |
| Generic name | Enzalutamide |
| Strength | 40 mg |
| Medicine class | Androgen-receptor inhibitor |
| Main therapeutic area | Prostate cancer |
| Route | Oral |
| Reference product strengths | 40 mg and 80 mg tablets |
| Reference adult dose | 160 mg once daily |
| Food | With or without food according to reference information |
| Company supplied for this product | Everest |
| Prescription status | Prescription medicine |
Enzalutamide is a targeted hormonal anticancer medicine with an established role in selected prostate cancer treatment settings. Enzamide 40 mg is identified in the supplied product information as an enzalutamide product associated with Everest. Product-specific authorization, manufacturing, packaging, and distribution information should always be confirmed from the actual product documentation and applicable regulatory authority.
Latest News
FAQs
Enzalutamide is an oral androgen-receptor inhibitor and targeted hormonal therapy used in specific prostate-cancer treatment settings. It works by interfering with androgen-receptor signaling involved in prostate-cancer growth.
Enzalutamide primarily works by blocking androgen-receptor signaling rather than directly lowering testosterone production. Depending on the treatment setting, it may be used together with androgen-deprivation therapy, which reduces androgen levels.
The duration of enzalutamide treatment varies between patients. Treatment may continue while the medicine remains appropriate and tolerated, according to the patient's disease status and the treating physician's plan.
Enzalutamide should not be described as a guaranteed cure for prostate cancer. Its purpose is to treat specific prostate-cancer conditions and help control androgen-receptor signaling. Treatment goals depend on the individual patient's disease and treatment plan.
Enzalutamide is generally taken once daily, and taking it at approximately the same time each day can help maintain a consistent routine. Follow the specific instructions provided by your prescribing healthcare professional.
Enzalutamide may be prescribed to appropriate older adults with prostate cancer. The healthcare professional should consider overall health, other medicines, cardiovascular history, neurological conditions, fall risk, and other individual factors before and during treatment.
Yes. Fatigue is a reported adverse effect of enzalutamide treatment. Patients experiencing persistent or severe tiredness, weakness, dizziness, or difficulty performing normal activities should discuss these symptoms with their healthcare professional.
Falls can occur during enzalutamide treatment. Dizziness, fatigue, weakness, age, reduced bone strength, and other health conditions may contribute to fall risk. Patients should tell their healthcare professional about repeated falls or balance problems.
Tell your doctor about your complete medical history, especially previous seizures, cardiovascular disease, hypertension, neurological conditions, allergies, and problems with falls or fractures. Provide a complete list of prescription medicines, over-the-counter products, vitamins, and supplements.
Yes. Regular follow-up is important during enzalutamide treatment. Your healthcare team may assess prostate-cancer status, treatment response, blood pressure, side effects, other medicines, and other health factors as appropriate.